
In 2 pivotal phase 3 studies, all 5 readers hit sensitivity and specificity targets for florquinitau F 18 tau PET, including in patients with early symptomatic Alzheimer disease.
Seems like a reasonable assessment...
Mr Hawkins is a cartoonist, whose latest book,



